Doliprane: “There will be no supply problem this winter,” assures the president of Sanofi

This is a relief for thousands of French people. The little yellow boxes will not be out of stock this winter. “I confirm it, there will be no problem because our factories operate 24 hours a day” to produce Doliprane, announced this Friday on RTL the president of Sanofi France, Audrey Derveloy. This doctor also assured that the laboratory “will continue to produce” this drug on French soil. Thanks to an investment of 20 million euros, Sanofi will be able to produce “140 million additional boxes of Doliprane”.

Before seeing these new boxes in pharmacies, Audrey Derveloy reminds us of the right actions to adopt to avoid shortages: “We do not overstock, there is no need and we should not do it.” “We all have to be responsible, at all levels: at home, at the pharmacist or at the wholesaler,” she adds. The president of Sanofi also explains that “manufacturing drugs is complex” and that “of the entire portfolio [of Sanofi], only 1% is in a shortage situation”.

Also read “It’s both cool and dramatic”: in the back rooms of pharmacies, the production of medicines is intensifying

In France, around 4,000 medications are out of stock or pre-out of stock in pharmacies, all laboratories combined. To avoid these situations, Audrey Derveloy details the mechanisms applied in times of tension such as a “stock quota” or discussions between the different health actors. “We work, [for example], with other laboratories to import alternative molecules,” mentions the president of Sanofi.

Asked whether the relocation of medicines to France would make it possible to avoid these shortages, Audrey Derlevoy expressed an incisive “no”. “We must not believe that there is a single solution that will solve” all the problems, she adds. For the doctor, “prevention” is the most important measure to follow, if the French want to avoid finding themselves deprived at pharmacy counters.